ArticleJournal of clinical medicine2026

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

David B Beck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.